Drug intelligence / Profile preview

ACX-14

Development stage: Preclinical
Lead developer: Applied Cognition
Modality: Small Molecules

Overview

ACX-14 is a small molecule therapeutic candidate being developed by Applied Cognition. It is designed to modulate neurovascular function and astrocyte-mediated neuropil resistance, targeting a novel druggable mechanism within the central nervous system. The program is currently in the discovery phase, with potential applications in treating Alzheimer's disease, Parkinson's disease, and various forms of dementia. By addressing neurovascular health and astrocyte-related resistance in the neuropil, ACX-14 aims to provide a new approach to managing neurodegeneration.

Beyond the preview

Go deeper on ACX-14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACX-14.

Explore the full profile